Real-world evidence (RWE) is now a regular part of health technology assessment in Europe and North America. In this article, first published in ISPOR’s Value & Outcomes Spotlight (July/August 2026), authors from six of ISPOR’s Latin American chapters argue that the region has plenty of health data. What it lacks is the governance, interoperability and…
With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems? Back in 2023, Barcelona was a somewhat surprising choice for AstraZeneca’s new global R&D hub. The Catalan capital, Spain’s second largest city, lacks both the Big Pharma footprint of a…
Samsung Bioepis is expanding in the US biosimilars market, with ten FDA approvals so far, seven assets in development, and an ambitious target of 20 products on the market by 2031. Tom Newcomer, SVP and Head of US Commercial, sets out why quality and supply reliability, rather than low prices, are at the heart of…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Asieris’ $250M deal with Theramex for APL-1702 (CEVIRA®), MicuRx’s $974M collaboration with ClearideBio for MRX-23 and ADC programs, and Defand’s partnership with Roche on molecular glue degraders. Other updates feature DualityBio’s IPO progress, Akeso’s Phase III NSCLC trial, and Zhongsheng’s RAY1225 achieving 22.2% weight…
“ We are no longer a purely Korean company; our ambition is to become a genuinely global player in epilepsy ”
“ I am confident that Germany will continue to offer the right conditions for long-term innovation and growth ”
“ We have transformed ourselves into a top 20 specialty pharmaceutical company globally ”
“ If we want Europe to remain a place where innovation arrives early rather than late, we need to work together ”
“ We are not here to maximise return on investment; we want to remain sustainable while doing something meaningful ”
“ Our vision remains very simple: to turn great science into medicines that can change patients' lives ”
“ My goal, and the FDA goal in general, is to make regulatory expectations so efficient that developers are willing to pursue biosimilars for non-blockbuster biologics. ”
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile geopolitical environment and with some…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions fully took off. That sustained…
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors – which have forced the island to adopt the most rigorous international standards and build a dense web of global partnerships – might ultimately be…
Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long overlooked it for trials. The opportunity is real; but so is the ground Japan still must make up. Japan’s importance to the global biopharmaceutical…
See our Cookie Privacy Policy Here
